ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome
PR95775
SEOUL, Korea, May 9, 2022 /PRNewswire=KYODO JBN/ --
-To lay a technological foundation for developing exosome-based medicines and
cosmetic products for dermatitis treatment
-To prove the technological feasibility of ExoSCRT(TM) for the mass-production
of the world's best exosomes with high efficacy
ExoCoBio Inc., one of global top 4 for stem cell exosome industry, announced
that it received from Japanese Patent Office the patent which claims that stem
cell-derived exosome is proved as effective ingredient for alleviating
dermatitis (The registration number is 6970459).
The patent is the result of the vigorous R&D efforts made to develop
therapeutic medicines with higher efficacy and safety than currently known ones
in relation to dermatitis with itching and inflammation. ExoCoBio found that
the technology in the patent would solve the safety problem arising from stem
cell or stem cell conditioned media by using ExoSCRT(TM) exosomes isolated from
adipose stem cell conditioned media and thus prove the effectiveness of
exosomes for prevention, improvement, alleviation or treatment of dermatitis.
Furthermore, it is anticipated that the ExoSCRT(TM) exosomes will play a
scientifically pivotal role as new medicine for dermatitis treatment.
Among therapeutic medicines currently marketed for the dermatitis are steroid,
antihistamine, and immunosuppressive cyclosporine A etc. There are, however,
growing concerns about serious side effects in relation with the use of them
such as atrophodermia, vasodilation, loss of pigment, hypersensitivity after
injection, tolerance and neutropenia etc. On the contrary, exosome-based
medicines are expected to provide the fundamental treatment for inflammatory
skin diseases without any serious side effect.
The key points of the patent cover following:
-ExoSCRT(TM) exosomes reduce the generation of inflammatory factors including
inflammatory cytokine which are main causes of dermatitis;
-ExoSCRT(TM) exosomes can be developed as active principles of medicine or
cosmetics to prevent, alleviate or treat the dermatitis by suppressing the
activity of inflammatory immune cells;
-ExoSCRT(TM) exosomes promote the ceramide biosynthesis that is a key factor of
skin barrier;
-It was scientifically proved that ExoSCRT(TM), technology developed by
ExoCoBio for stem cell exosome production, plays a key role in producing high
quality exosomes;
In connection with the patent, ExoCoBio published an article in the journal of
Stem Cell Research & Therapy in 2018 according to which ExoSCRT(TM) exosomes
alleviate atopic dermatitis with antibodies against surface markers (CD9, CD63,
and CD81) (for the article, please visit the following:
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0939-5).
Additionally, as a supporting document, ExoCoBio published an article in the
journal of Cells in 2020, according to which ExoSCRT(TM) exosomes promote de
novo synthesis of ceramides in atopic dermatitis (for the article, visit the
following: https://pubmed.ncbi.nlm.nih.gov/32164386/).
ExoCoBio expects that the patent will lay a technological foundation for
regenerative aesthetics and medicines relating to prevention, alleviation or
treatment of dermatitis. Furthermore, ExoCoBio anticipates its business
opportunity in Japan for ExoSCRT(TM) exosomes based on the patent in the
cosmetic and pharmaceutical fields.
SOURCE: ExoCoBio Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。